Geodon Articles
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
US Court imposes record fine and forfeiture of $1.3 billion for Pfizer unit’s fraudulent marketing of Bextra
19 October 2009
Strong AE profile for Vanda's iloperidone
19 May 2008
Patent expiries will reduce bipolar drug market $400M
1 October 2007
Pfizer
23 July 2007
Lupin's generic ziprasidone approved in USA
28 May 2007
Pfizer's 1st-qtr profits tumble 17.5%
30 April 2007
Lilly maintains cost-effectiveness of Zyprexa
11 December 2006
New hope for sufferers of manic-depression from unlikely sources
4 December 2006
Pfizer
31 July 2006
Pfzizer's Geodon fares well vs placebo and Zyprexa
15 August 2005
Corcept's Corlux shows good weight loss result
25 April 2005
Pfizer's Geodon gets FDA OK for new use
30 August 2004
Israel: complaints over funds' drug access
23 August 2004
FDA appro for Lilly's injectable Zyprexa
5 April 2004
Pfizer submits sNDA for Geodon to FDA
16 February 2004
Lilly receives product labeling letter from FDA
29 September 2003
Injectable form of Geodon cleared in USA
1 July 2002
UK pharma news in brief
22 April 2002
Pfizer to launch Zeldox in other EU markets
4 March 2002
J&J files for depot form of Risperdal
6 September 2001
Zyprexa and Prozac effective together
11 May 2001
Injectable Zyprexa backed in USA
16 February 2001
Stock Commentary - New York
15 February 2001
Pfizer's antipsychotic ziprasidone gets approval in USA
7 February 2001
EU approval delay for Pfizer's Zeldox
28 December 2000
Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting
14 December 2000
Pfizer's Zeldox approvable in USA
14 September 2000
Pfizer gains Swedish OK for intramuscular Zeldox
8 September 2000
Pfizer named company of the year by Forbes
31 December 1998
Pfizer Aims For Top Slot After Millenium
10 November 1998
Pfizer Pulls Zeldox Application
28 July 1998
First Approval For Pfizer's Zeldox
16 July 1998
Stock Commentary New York
2 July 1998
FDA Says Pfizer's Zeldox Is "Non-Approvable"
24 June 1998
Minor Setback With Droloxifene For Pfizer
29 January 1998
New Products In 1998; A Look Ahead
6 January 1998
Pfizer's Healthy Growth Lifted By Alliance Products
16 October 1997
Pfizer Enters New Product Cycle With Strong Potential
7 August 1997
Zeneca's Seroquel Gains UK Approval, Its First
5 August 1997
Zeneca's Seroquel Nears Market Approval
16 July 1997
Progress With Pfizer's Ziprasidone
3 July 1997
Continued Approval Of Blockbuster Products In '97?
23 December 1996
Zoloft Gets OCD Indication
4 November 1996
Zeneca Files First European Seroquel Dossier
19 August 1996
Ziprasidone May Have Unique Neuroleptic Activity
8 July 1996
First Appro Of Sertindole In UK; Launch Imminent
1 July 1996
Phase III Data With Lilly's Olanzapine
8 January 1996
Zeneca Reveals Typically Strong Pipeline
18 December 1995
Pfizer Presents Fertile Pipeline
6 November 1995
Pfizer's Fruitful Product Pipeline
7 November 1994
Pfizer: Record Number Of Drugs In Phases II & III
31 October 1994
PFIZER "CONFIDENT" IN CHANGING ENVIRONMENT
3 May 1993
Showing 1-83 of 83 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
